Dyskeratosis congenita (DKC) is caused by mutations in genes that control telomere homeostasis, and is characterised by clinical symptoms ranging from bone marrow failure to pulmonary fibrosis and cancer. Disease features vary with the affected gene, but are all thought to result from defects in the function of tissue stem cells. Although mouse models have provided some insight regarding underlying mechanisms, human studies are an essential component of research on DKC and will be required for developing new therapies. Batista et al. report that induced pluripotent stem cells (iPSCs) derived from fibroblasts of patients with DKC exhibit defects that mirror the biochemical features of the patients’ cells, including impaired telomere homeostasis. The authors probed distinct pathological mechanisms underlying the disease using iPSCs derived from five patients carrying diverse mutations (in TERT, TCAB1 and DKC1), and found that the extent of the defects observed in the iPSCs correlated with clinical disease severity. The findings suggest that restoring telomere homeostasis in tissue stem cells might be a promising therapy for DKC. They also support the application of iPSC-based systems to study other diseases caused by stem-cell defects.
Diseases of tissue stem cells: human iPSCs provide new clues
Diseases of tissue stem cells: human iPSCs provide new clues. Dis Model Mech 1 July 2011; 4 (4): 422. doi:
Download citation file:
Advertisement
Cited by
Call for Papers – Infectious Disease: Evolution, Mechanisms and Global Health
Showcase your latest research on our upcoming Special Issue: Infectious Disease: Evolution, Mechanisms and Global Health. This issue will be coordinated by DMM Editors Sumana Sanyal and David Tobin alongside Guest Editors Judi Allen and Russell Vance. The deadline for submitting articles to this Special Issue has been extended to Monday 24 February 2025.
Biologists @ 100 - join us in Liverpool in March 2025
We are excited to invite you to a unique scientific conference, celebrating the 100-year anniversary of The Company of Biologists, and bringing together our different communities. The conference will incorporate a DMM programme on antimicrobial resistance on 26 March 2025. Find out more and register to join us in March 2025 in Liverpool, UK. The deadline for abstract submission and early-bird registration is 17 January 2025.
It's about time: the heterochronic background for the 2024 Nobel Prize in Physiology or Medicine
In this Editorial, Bruce Wightman writes about the groundwork laid by investigating the timing of developmental events in nematodes which led to the 2024 Nobel Prize in Physiology or Medicine.
Read & Publish Open Access publishing: what authors say
We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Other journals from
The Company of Biologists